Clinical trial NCT00247975: Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy
Official title: Primary Prevention of Anthracycline-Induced Cardiotoxicity With L-Carnitine in Patients With Breast Cancer (PPACC)-Pilot Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Heart Failure
Keywords: L-carnitine
Breast cancer
Anthracycline Cardiotoxicity
Primary prevention
Anthracycline induced cardiotoxicity
Left Ventricular Ejection Fraction
Lead sponsor: Ottawa Heart Institute Research Corporation
Sponsor class: OTHER
Collaborators: name: Canadian Institutes of Health Research (CIHR)
First posted: 2005-11-02
Enrollment: 36
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Breast cancer is very common and afflicts 1 in 9 North American women. The treatment of breast cancer often requires the use of chemotherapy including "anthracyclines". Anthracyclines can damage the heart resulting in heart failure and even death. Clinicians and researchers are continually seeking methods that will reduce the toxic effects of anthracycline treatment.

L-carnitine is a substance that is produced naturally in the body and is required for normal heart function. Animal studies have suggested that L-carnitine protects the heart from the effects of anthracyclines, however this has not been verified in humans.

This study will assess the potential role of L-carnitine in the prevention of anthracycline induced heart damage. The investigators will enroll 144 patients into this study. Patients will be randomly assigned to L-carnitine therapy or to standard care (no L-carnitine therapy). Patients in the L-carnitine group will receive oral and intravenous L-carnitine prior to and after their anthracycline therapy. Patients will undergo regular follow up and testing to assess heart function. The investigators believe that patients treated with L-carnitine will benefit and have fewer complications associated with anthracycline treatment.


Eligibility criteria: Inclusion Criteria:

* Female patients must have histologically or cytologically indicated breast cancer (stages I, II, III) eligible for adjuvant anthracycline chemotherapy \[FEC100 or AC-Taxol(paclitaxel) every 21 days.
* HER2 negative or HER2 positive breast cancer by immunohistochemistry (IHC3+) and/or fluorescent in-situ hybridization.
* Eastern cooperative oncology group (ECOG) performance status = 0, 1, 2
* Age ≥ 18 years old.
* Ability to understand and the willingness to sign a written informed consent document.
* The effects of L-carnitine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

Exclusion Criteria:

* Patients with evidence of metastatic breast cancer.
* Resting LV ejection fraction \< 50%.
* Patients having received previous anthracycline therapy or contraindication to anthracycline.
* Patients having a contraindication to L-carnitine therapy
* Dexrazoxane therapy at the time of enrollment.
* Patients with abnormal baseline bloodwork:

  * hemoglobin ≤ 100 mg/L
  * platelets ≤ 100 x 10\^9/L
  * white blood cells ≤ 4 x 10\^9/L
  * creatinine, AST, ALT, bilirubin \> 1.5 x the upper normal limits
* Participation in another randomized clinical trial.
* Patients having significant cardiac disease (previous myocardial infarction, congestive heart failure, or hemodynamically significant valvular heart disease) that would limit compliance with study requirements.
* Patients taking medication that may affect LV function (b-blockers, amiodarone, ACE-inhibitors, calcium channel blockers, or digoxin).
* Patients with symptoms of heart failure.
* Patients unable to participate in a study requiring long term follow up.
* Pregnant or lactating women.

Primary outcomes:
measure: To compare the effects of L-carnitine therapy versus placebo on left ventricular (LV) ejection fraction (EF) as a marker of anthracycline induced cardiotoxicity
timeFrame: 1 year
Secondary outcomes:
measure: To compare the effects of L-carnitine therapy versus placebo on: other potential markers of anthracycline induced cardiotoxicity such as LV volume, LV systolic and diastolic function, troponin T (TnT) and NT-pro-brain natriuretic peptide (BNP)
timeFrame: 1 year
measure: "Anthracycline-induced cardiotoxicity" and clinical cardiac outcomes
timeFrame: 1 year
measure: Serum L-carnitine levels
timeFrame: 4 months
measure: To assess: the safety of L-carnitine
timeFrame: 1 year
measure: the predictive value of serum biomarkers (TnT, BNP, and L-carnitine levels) for cardiotoxicity and cardiac outcome (ejection fraction, LV volumes, congestive heart failure, and cardiac death)
timeFrame: 1 year
measure: the effect of anthracyclines on plasma L-carnitine levels
timeFrame: 4 months
measure: the correlation of L-carnitine levels with serum TnT and BNP levels
timeFrame: 4 months
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: University of Ottawa Heart Institute
state: Ontario
Study officials:
affiliation: Ottawa Heart Institute Research Corporation
name: Benjamin JW Chow, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
affiliation: Ottawa Heart Institute Research Corporation
name: Rob S Beanlands, MD, FRCPC
role: STUDY_CHAIR
affiliation: Ottawa Heart Institute Research Corporation
name: Haissam Haddad, MD, FRCPC
role: STUDY_CHAIR
affiliation: Ottawa Heart Institute Research Corporation
name: George Wells, M.Sc., PhD
role: STUDY_CHAIR
affiliation: Ottawa Regional Cancer Centre
name: Susan Dent, MD, FRCPC
role: STUDY_CHAIR
affiliation: Ottawa Regional Cancer Centre
name: Sean Hopkins, B.Sc, RPEBC
role: STUDY_CHAIR
affiliation: Ottawa Hospital
name: Michele A Turek, MD, FRCPC
role: STUDY_CHAIR
References: